- Worldwide orphan drug sales forecast to total $209bn (CAGR 2017 to 2022:+11.1%)
- Orphan drugs set to be 21.4% of worldwide prescription sales by 2022 (excluding generics)
- Median cost per patient 5.5 times higher for orphan drugs compared to non-orphan
- Celgene set to climb to number one position in orphan drug sales to 2022
- Shire to be largest company by sales in the orphan non-oncology space in 2022
- AstraZeneca, Abbvie and Johnson & Johnson set to march up the orphan drug sales ranking table
- Revlimid (lenalidomide) No.1 orphan drug in 2022
- Opdivo (nivolumab) No.1 orphan drug in Europe in 2022
- Orphan drugs forecast to account for 55% of the cumulative value of the European pipeline to 2022
- Axicabtagene Ciloleucel (Kite Pharma) is most valuable R&D orphan drug
- First decline since 2012 for FDA orphan designations in 2016 with 333; Record number of applications made to the FDA for orphan designation in 2016
The “EvaluatePharma Orphan Drug Report 2017” can be downloaded at: www.evaluategroup.com/orphandrug2017.